

1 **INTEGRATED NCDs TREATMENT AND CARE AMONG PEOPLE LIVING WITH**
2 **HIV/AIDS ATTENDING CARE AND TREATMENT AT A HEALTH FACILITY**

3

4 Atuganile Musyani^{1 2}, Grace Mosi^{1 2}, Erik Kinyenje^{1 2}, Albertino Damasceno⁵, Mucho
5 Mizinduko², Rogath Kishimba^{1 3}, Meshack Shimwela⁴, Leonard Subi³.

6

7 ⁴ Temeke Regional Referral Hospital

8 ³ Ministry of Health Community Development Gender Elderly and Children

9 ¹ Tanzania Field Epidemiology and Laboratory Training Programme

10 ² Muhimbili University of Health and Allied Sciences

11 ⁵Eduardo Mondlane University-Maputo, Mozambique

12

13 **ABSTRACT**

14 **Introduction:**

15 Persons living with HIV (PLHIV) in Tanzania now live longer due to the advancement of HIV
16 care programs. For this reason, they are at an increased risk of developing Non-Communicable
17 Diseases (NCDs). Despite many resources committed to HIV care programs, NCDs care is not
18 effectively integrated into these programs. The study aimed at describing missed opportunities to
19 diagnose and manage hypertension and diabetes and implementing and evaluating the effect of
20 three months of preventive efforts among among PLHIV attending care and treatment centers
21 (CTC)

22

23 **Materials and methods:**

24 We evaluated 333 PLHIV attending CTC for blood pressure and blood sugar levels. Patients who
25 were diagnosed with high blood pressure equal to or above 140/90 mm Hg, or on treatment for
26 hypertension and a fasting blood sugar above 7.0 mmol/L (126 mg/dl) were subjected to a small
27 intervention aimed at increasing health literacy on the adherence to and control of their
28 pathologies. Re-evaluation of their blood pressure and blood sugar levels was done at the end of a
29 3 months intervention.

30

31 **Results:**

32 Of the evaluated 333 PLHIV, 71 (21.32%) had hypertension and 9 (2.70%) had high blood sugar.
33 Among 177 PLHIV who never had their BP measured before, 37/177 (20.90%) were diagnosed
34 with hypertension. The cohort group involved analysis of 76 patients with either uncontrolled
35 hypertension or diabetes followed for three months. By the end of the 3rd month of intervention,
36 26/71 (36.6%) were able to control their blood pressure (BP < 140 SBP and < 90 DBP). The mean
37 blood pressure decreased from 164/99.5 mmHg to 159 /96mmHg. Of the 9 PLHIV with high blood
38 glucose levels, 5/9 (55.5%) had their blood sugar normalized at the end of the intervention. In a
39 focused group discussion, most patients reported difficulties in controlling their BP due to the high
40 cost of medication and consequently poor adherence to medication.

41

42 **Conclusion:**

43 The burden of undiagnosed NCDs among PLHIV attending care and treatment clinic is remarkably
44 high. Interventions to address such diseases in CTC seem to work. HIV care and treatment
45 programs should provide integrated care that includes NCDs care.

46 INTRODUCTION

47 Global Non-Communicable Diseases (NCDs) burden remains unacceptably high (1). In 2016,
48 NCDs were responsible for 41 million of the world's 57 million deaths (71%), where 44% were
49 due to cardiovascular diseases (CVD) and 4% were due to diabetes (2). CVD and diabetes caused
50 31% and 3% respectively of all deaths globally (3). Deaths due to NCDs are expected to increase
51 to 55 million by 2030 (4). In Tanzania in 2016, among 409,000 deaths, 134,970 (33%) were due
52 to NCDs (5). Of these, (17,546) 13% and (2700) 2% were due to CVD and diabetes mellitus,
53 respectively (6).

54 Due to the advancement of HIV care programs, persons living with HIV (PLHIV) now live longer
55 (7). For this reason, they are at increased risk of developing Non-Communicable Diseases (NCDs)
56 such as hypertension (HTN) and type 2 diabetes mellitus (T2DM) like other persons due to aging.
57 In addition to the increased risk due to aging, the HIV disease itself and anti-retroviral treatment
58 (ART) use add more risk of NCDs to PLHIV (8–10). Chronic immune activation due to the virus
59 and medication side effects are critical mechanisms that lead to this increased risk (11).
60 Cardiovascular disease is the leading cause of non-AIDS-related morbidity and mortality among
61 PLHIV (11). Diabetes affects PLHIV almost twice as often as persons without HIV (12–14).
62 Patients with multiple comorbidities can benefit by providing integrated care for all the diseases
63 at a single point of care (15–17). Different studies have shown that an integrated platform of care
64 is very crucial in addressing NCDs (17–20).

65 The prevalence of HIV in Tanzania in 2018 was estimated to be at 4.6% (21). This translated into
66 about 1.4 million children and adults living with the infection in the country. There has been a
67 progressive decline in the number of AIDS-related deaths in the past decade with overall AIDS-

68 related mortality decreasing by 50%, from 48,000 deaths in the year 2010 to 24,000 deaths in the
69 year 2018 (21).

70

71 HIV care programs have many resources in contrast with NCDs care that is poorly financed and
72 is not effectively integrated into the HIV care programs (22,23). The country experiences a lack
73 of evidence-based care model for scaling up integrated HIV/NCDs care (2). This is due to
74 inadequate or absence of effective monitoring and evaluation systems (poor NCD surveillance)
75 and inadequate use of health information regarding NCDs (15). The country has weak chronic
76 disease care health system which is not patient-centered, resulting in ineffective control of chronic
77 diseases among all and also among PLHIV (15). There are often inadequate multi-sectoral
78 responses to the diseases, inadequate resources (human, infrastructures, and funds), poor
79 governance and leadership, and low capacity of health service providers in terms of knowledge,
80 skills, and numbers (22).

81 Our project, therefore, aimed at describing missed opportunities to diagnose and care for
82 hypertension (HTN) and diabetes (DM) among PLHIV attending CTC in Dar es Salaam, Tanzania,
83 and implementing and evaluating hypertension and diabetes mellitus preventive efforts among
84 these patients.

85

86

87

88 **MATERIALS AND METHODS**

89 **Project design:**

90 This was a facility-based screening program for hypertension and diabetes among PLHIV
91 receiving care at CTC in Dar es Salaam, Tanzania. It was conducted from January to June 2020.

92

93 **Project setting:**

94 The project was carried out at CTC at Temeke Regional Referral Hospital (Temeke RRH). Temeke
95 RRH is a public owned hospital that is located in the southern part of Dar es Salaam region, the
96 largest commercial city located in the Eastern part of Tanzania. Although the hospital has
97 specialized diabetic, cardiovascular, and CTC clinics, the services are not integrated. Patients who
98 have been diagnosed with HTN or diabetes in an HIV clinic are referred for care in these separate
99 clinics within the hospital settings.

100

101 **Target population:**

102 The target population was PLHIV aged 18 years or above attending Temeke RRH in Temeke
103 District in Dar es Salaam, Tanzania. We used convenient sampling to select PLHIV who attended
104 CTC within the 5 days of data collection. Clients were randomly selected based on availability at
105 the time of interview. The project excluded pregnant women living with HIV/AIDS and patients
106 with mental diseases.

107

108 **Project variable:**

109 Data collected involved demographic information, blood pressure and biochemical measurements
110 (Blood glucose level and cholesterol level). The project also involved a short discussion for

111 exploring the factors leading to poor adherence to hypertensive and diabetic medication. The
112 primary outcome at various time points were missed opportunities for diagnosis and care for NCDs
113 among PLHIV. Secondary outcomes were control rates of hypertensive and diabetic patients at the
114 end of a three month intervention.

115

116 **Blood pressure and glucose measurements:**

117 Blood pressure and glucose level were measured following the Tanzania national guidelines.
118 Blood pressure (BP) was measured by trained personnel using a standardized protocol and
119 validated and regularly calibrated electronic sphygmomanometers (Omron HEM-7270). Blood
120 sugar levels were measured using rapid methods (Accu-chek®). Fasting and random blood sugar
121 level was used and diagnosis was based on Tanzania national guideline. Fasting blood glucose was
122 considered when patient reported not eating for more than 8 hours. Blood pressure was checked
123 three times, 5 minutes after arrival to the clinic, during triaging at the triage desk (approximately
124 30 minutes later), and at the consultation desk with a doctor. The mean of the three measurements
125 of blood pressure were used for diagnosis of hypertension. Hypertension and T2DM were defined
126 according to the Tanzania national guideline (9). Hypertension was defined as blood pressure (BP)
127 equal to or above 140/90 mmHg, T2DM was defined as raised fasting blood sugar of 7.0 mmol/L
128 (126 mg/dl) or more or a random blood sugar equal or above 11.1 mmol/L (200 mg/dL). Blood
129 pressure control was defined as when the systolic BP was below 140mmHg and diastolic BP below
130 90 mm Hg on anti hypertension treatment. DM was defined as being controlled when fasting blood
131 glucose was below 6 mmol/L.

132

133 **Enrolled in a follow-up group:**

134 A cohort of 76 patients with HTN and T2DM/high blood glucose levels during the current project
135 was followed for three months. At each clinic visit, patients received health education on
136 hypertension and DM. Individuals with hypertension were managed using a clinical and
137 medication management algorithm based on the Tanzania clinical guideline (9). Participants
138 diagnosed with diabetes were encouraged to do a lifestyle change. The patient's registry was
139 developed following recommendations from the HEARTS technical package of the World Health
140 Organization (WHO) and Tanzania national guideline with some modification (10,11). A simple
141 surveillance system was developed for all patients diagnosed with HTN and T2DM. All 76 patients
142 had complete data and were involved in the analysis at the end of the study.

143 *Figure 1: The diagram showing the PLHIV diagnosed with hypertension, DM or both and*
144 *enrollment into the cohort group for follow-up.*

145

146 **A focus group discussion:**

147 A focus group discussion was conducted to ascertain participant knowledge about BP control and
148 reasons for poor blood pressure control. A convenience sample of patients was identified that
149 included 10 clients and 10 health care workers.

150

151 **Analysis of data:**

152 Data were entered and cleaned using Epi info version 7, and then analyzed using STATA version
153 15 for Windows (Stata Corp., College Station, TX, USA). Descriptive statistics such as median
154 (with interquartile range) and frequencies (with percentages) were used to illustrate the baseline
155 characteristics of participants with the relevant variables. A short description of qualitative

156 information was reported. Missing data were excluded from the analysis. Chi-square test was used
157 to compare categorical variables between intervention and non-intervention group in relation to
158 hypertension and diabetes diagnosis outcome. Fisher's exact test was used where appropriate. The
159 null hypothesis was that, there was no difference in distribution of characteristics between
160 intervention and non-intervention group. An alternative hypothesis was that, at least one
161 characteristics was related to intervention and non-intervention group. Binary logistic regression
162 was used to ascertain association between the independent and dependent variables. All
163 independent variables with a P value ≤ 0.1 in the bivariate analyses were included in the final
164 multivariable logistic model in order to identify the risk factors for getting hypertension and
165 diabetes. All variables which attained a p-value <0.05 was considered statistically significant. A
166 paired t-test was conducted on the measurements of 76 participants (systolic and diastolic pressure,
167 BMI, and fasting blood glucose levels) to determine if measurements at month three were different
168 from those taken at baseline to ascertain the effectiveness of the intervention.

169

170 **Ethical consideration:**

171 An ethical clearance to conduct this project was obtained from the Muhimbili University of Health
172 and Allied Sciences Institutional Research Board. Permission to conduct the study at Temeke
173 Regional Referral Hospital was obtained from the Medical Officer In-charge. All participants gave
174 informed consent to participate in the project after a thorough description of the study objectives
175 and risks associated with participation. The project ensured privacy and confidentiality to all
176 participants.

177 RESULTS:

178 3.1. Demographic and Clinical Characteristics of the Study Participants.

179 Study size:

180 A total of 335 PLHIV participated in the interview, with two (2) participants removed from the
181 analysis due to incomplete information.

182
183 A total of 333 patients were included in the evaluation for hypertension and blood sugar levels.
184 Demographic and clinical characteristics were compared between patients diagnosed with diabetes
185 and hypertension (intervention group) and those not diagnosed with either diseases (control group)
186 as shown in *table 1*. The median age (IQR) for the study participants was 46 (39-52) years. There
187 was a significant age difference between intervention and control group (*P-value 0.02*). The
188 intervention group were a bit older with a median age (IQR) of 48 (42-58) compared to the control
189 group median (IQR) age of 46 (38-51). Except for age, body mass index and waist hip ratio which
190 showed a significant difference between intervention and control group, there no significant
191 difference in all other variables between the two groups (*Table 1*).

192
193 **Table 1: Demographic and Clinical characteristics of patients diagnosed and not diagnosed**
194 **with hypertension and diabetes among people living with HIV/AIDS attending Care and**
195 **Treatment Center in Dar es Salaam, Tanzania in 2020**

Characteristics	Overall (N 333)	Intervention group (N 76 (22.82%))	Control group (N 257 (77.18%))	P-value
Median age (SD)	46 (39-52)	48 (42-58)	46 (38-51)	
Age group in years, n (%)				
18-39	84 (25.23)	11 (11.47)	73 (28.40)	0.02
40-49	141 (42.34)	32 (42.11)	109 (42.41)	

50-75	108 (32.43)	33 (43.42)	75 (29.18)	
Marital status				
Single	72 (21.62)	13 (17.11)	59 (22.96)	0.25
Married/Cohabiting	118 (35.44)	23 (30.26)	95 (36.96)	
Divorced/Separated	87 (26.13)	23 (30.26)	64 (24.90)	
Widowed	56 (16.82)	17 (22.37)	39 (15.18)	
Residence, n (%)				
Temeke	277 (83.18)	66 (86.84)	211 (82.10)	0.33
Other districts	56 (16.82)	10 (13.16)	46 (17.90)	
Education level, n (%)				
Not educated	37 (11.11)	10 (13.16)	27 (10.51)	0.80
Primary School	236 (70.87)	55 (72.37)	181 (70.43)	
Secondary School	53 (15.92)	10 (13.16)	43 (16.73)	
College/University	7 (2.10)	1 (1.32)	6 (2.33)	
Duration since HIV Diagnosis				
≤ 5 years	73 (21.92)	11 (14.47)	62 (24.12)	0.07
>5 years	260 (78.08)	65 (85.53)	195 (75.88)	
HIV Stage on diagnosis				
Stage 1	58 (17.42)	16 (21.05)	42 (16.34)	0.29
Stage 2	87 (26.13)	15 (19.74)	72 (28.02)	
Stage 3	162 (48.65)	41 (53.95)	121 (47.08)	
Stage 4	26 (7.81)	4 (5.26)	22 (8.56)	
CD4 count on diagnosis				
0-200	60 (18.02)	12 (15.79)	48 (18.68)	0.16
201-350	48 (14.41)	17 (22.37)	31 (12.06)	
351-2000	81 (24.32)	16 (21.05)	65 (25.29)	
Not documented	144 (43.24)	31 (40.79)	113 (43.97)	
Duration on ART, n (%)				
0-1 year	42 (12.61)	7 (9.21)	35 (13.62)	0.66
2-4 years	89 (26.73)	21 (27.63)	68 (26.46)	
> 5 years	202 (60.66)	48 (63.16)	154 (59.92)	
Current ART used, n (%)				

First-line	297 (89.19)	67 (88.16)	230 (89.49)	0.85
Second line	12 (3.60)	3 (3.95)	9 (3.50)	
Not documented	24 (7.21)	6 (7.89)	18 (7.00)	
Viral load, n (%)				
Suppressed	289 (86.79)	66 (86.84)	223 (86.77)	0.91
High viral load	12 (3.60)	2 (2.63)	10 (3.89)	
Not documented	32 (9.61)	8 (10.53)	24 (9.34)	
Tobacco use, n (%)				
Current tobacco user	17 (5.11)	1 (1.32)	16(6.23)	0.09
Not using tobacco	316 (94.89)	75 (98.68)	241 (93.77)	
Alcohol use, n (%)				
Current alcohol users	26 (7.81)	6 (7.89)	20 (7.78)	0.97
Not using alcohol currently	307 (92.19)	70 (92.11)	237 (92.22)	
Mean Body mass index (kg/m2)				
(SD)	25.95 (5.70)	28.15 (5.71)	25.30(5.55)	
Body mass index (kg/m2), n (%)				
Underweight	10 (3.00)	0 (0.00)	10 (3.89)	<0.01
Normal	160 (48.05)	27 (35.53)	133 (51.75)	
Overweight	92 (27.63)	23 (30.26)	69 (26.85)	
Obese	71 (21.32)	26 (34.21)	45 (17.51)	
Waist Hip Ratio				
Recommended ratio	110 (33.03)	18 (23.68)	92 (35.80)	0.05
Abdominal obesity 1	86 (25.83)	27 (35.53)	59 (22.96)	
Abdominal obesity	137 (41.14)	31 (40.79)	106 (41.25)	
Physical activities, n (%)				
Met WHO Standard	86 (25.83)	29 (32.22)	57 (23.46)	0.11
Did not meet the WHO standard	247 (74.17)	61 (67.78)	186 (76.54)	

196 Overweight=BMI between 25.0 -29.9, Obese=BMI \geq 30.0, HTN=BP \geq 140/90, Isolated Systolic HTN =Systolic
 197 BP>140, diastolic BP< 90, Isolated Diastolic HTN-Diastolic BP>90, systolic BP <140, Suppressed viral load=Viral
 198 load<1000 copies/MLS, High viral load=Viral load \geq 1000 copies/MLS, Physical activities-WHO recommendation-

199 An equivalent combination of moderate- and vigorous-intensity physical activity achieving at least 600 MET-
200 minutes, Diabetes-Fasting plasma glucose level ≥ 7.0 mmol/L

201

202 Overall, of 333 participants, 71/333 (21.32%) participants had hypertension and 9/333 (2.70%)
203 were diabetic. Four 4/333 (1.20%) participants were diagnosed with both hypertension and
204 diabetes. Of the 71 patients with hypertension, only 34/71 (47.89%) knew they had hypertension
205 and only 5 (7%) were already on treatment but had not achieved blood pressure control. Over
206 half of the study participants 177/333 (53.15%) have reported never having their blood pressure
207 measured before, and among these 37/177 (20.90%) were newly diagnosed with hypertension.
208 Overall, of the 9 participants with diabetics, 4/9 (44.44%) knew they had diabetes and were on
209 treatment and 5/9 (66.67%) were diagnosed during the study.

210

211 The prevalence of hypertension was significantly higher in patients older than 40 years (32/71
212 (42.11) and 50 years (33/71, 43.42%) compared to the younger counterparts aged less than 39
213 years (11/71, 11.47%; $P < 0.05$).

214

215 **Univariate and Multivariate analysis:**

216 Univariate and multivariate analyses results are shown in Table 2. All variable with crude OR of
217 equal or more than 0.1 in the univariate analysis were subjected to multivariate analysis. In the
218 analysis of risk factors, obese patients were 4 times as likely to have hypertension (AOR = 3.67;
219 95%CI: 1.64 – 8.17) compared to patients with normal body weight. This finding was significant
220 even after controlling for other confounder including age, gender. People above 40 and 50 years
221 were twice at risk each of getting hypertension compared to people aged below 40 years (AOR
222 1.76 95%CI 0.71-3.35 and AOR 2.48 95%CI 0.96-6.42 respectively). People with diabetes

223 mellitus were 5 times at significant risk of getting hypertension although the sample size was not
 224 adequate for comparison (AOR 5.30 95%CI 1.04-26.98).

225

226 **Table 2: Association between risk factors and elevated blood pressure or blood glucose**
 227 **among people living with HIV/AIDS attending Care and Treatment Center in Dar es**
 228 **Salaam, Tanzania in 2020**

Characteristics	Crude OR	P-value	95% CI	Adjusted OR	P-value	95% CI
Sex						
Male	1			1		
Female	1.50	0.21	0.80-2.81	1.05	0.89	0.48-2.27
Age group in years						
18-39	1			1		
40-49	1.79	0.13	0.85-3.80	1.76	0.22	0.71-4.34
50-75	2.59	0.02	1.19-5.46	2.48	0.06	0.96-6.42
Residence,						
Other districts	1					
Temeke	1.30	0.69	0.62-2.72			
Marital status						
Single	1					
Married/Cohabiting	0.98	0.96	0.46-2.12			
Divorced/Separated	1.44	0.35	0.66-3.14			
Widow/Widower	1.82	0.16	0.79-4.18			
Education level						
Primary School	1					
Not educated	0.98	0.96	0.43-2.26			
Secondary School	0.82	0.61	0.61-1.75			

College/University	0.59	0.63	0.07-5.01			
HIV Stage on diagnosis						
Stage 1	1			1		
Stage 2	0.50	0.10	0.22-1.13	0.41	0.08	0.16-1.11
Stage 3	0.86	0.66	0.44-1.60	0.69	0.39	0.30-1.61
Stage 4	0.15	0.04	0.01-0.84	0.07	0.03	0.01-0.72
Duration on ART						
≤ 5 years	1					
> 5 years	1.09	0.75	0.64-1.86			
Viral load						
Suppressed	1					
High viral load	0.73	0.69	0.16-3.43			
Tobacco use						
Not using tobacco	1					
Current tobacco user	0.22	0.15	0.03-1.69			
Alcohol use						
Not using alcohol	1					
Current alcohol users	1.12	0.82	0.43-3.05			
Body mass index (kg/m ²)						
Underweight	Omitted			Omitted		
Normal	1			1		
Overweight	1.59	0.16	0.83-3.05	1.73	0.19	0.76-3.92
Obese	2.93	<0.01	1.54-5.61	3.67	<0.01	1.64-8.17
Physical activities (WHO)						
Met Standard	1					
Did not meet the standard	1.25	0.48	0.67-2.33			
Diabetes mellitus						
Normal blood sugar	1			1		
Diabetic	3.28	0.09	0.85-12.68	5.30	0.05	1.04-26.98

229 Overweight=BMI between 25.0 -29.9, Obese=BMI \geq 30.0, HTN=BP \geq 140/90, Isolated Systolic HTN =Systolic
 230 BP>140, diastolic BP< 90, Isolated Diastolic HTN-Diastolic BP>90, systolic BP <140, Suppressed viral load=Viral
 231 load<1000 copies/MLS, High viral load=Viral load \geq 1000 copies/MLS, Physical activities-WHO recommendation-
 232 An equivalent combination of moderate- and vigorous-intensity physical activity achieving at least 600 MET-
 233 minutes, Diabetes-Fasting plasma glucose level \geq 7.0 mmol/L

234
 235 All patients included in the cohort (76) had completed data and were available for analysis at the
 236 end of the 3 month study.

237
 238 After three months of intervention, the mean change in blood pressure for study participants was
 239 from 164 to 159 mm/Hg for systolic blood pressure and 100 to 96 mm/Hg for diastolic blood
 240 pressure. Blood sugar level of patients who were diagnosed to be diabetic changed from the mean
 241 value of 11.96 to 9.38 mmol/L. Also for BMI, the change was from 28.9 to 27.5 kg/m². (**Table 3**)

242
 243 **Table 3: The effects of three months of preventive efforts in 76 HIV positive patients with**
 244 **elevated blood pressure or blood glucose attending Care and Treatment Center in Dar es**
 245 **Salaam, Tanzania in 2020**

Physical and biochemical measurements	Baseline measurements (mean \pm SD)	Measurements at three months (mean \pm SD)	P-value
Diastolic pressure (mm/Hg)	99.52 \pm 14.23)	95.76 (12.51)	< 0.01
Systolic pressure (mm/Hg)	164.28 \pm 21.62	158 \pm 21.23	0.01
Fasting blood level (mmol/L)	5.47 \pm 2.85	5.41 \pm 2.57	0.82
BMI (Kg/m ²)	28.89 \pm 8.39	27.46 \pm 5.60	0.08

246

247 Results for a paired t-test showed a significant decrease in mean systolic blood pressure ($t = 3.07$
 248 $w/df=81, p < 0.01, 95\%CI (2.01, 9.45)$) and mean diastolic blood pressure ($t=2.91 w/df=81, p < 0.01,$
 249 $95\%CI (1.19, 6.33)$). There was no statistically significant difference in mean FBG level ($t=0.03$
 250 $w/df=81, p = 0.82, 95\%CI (-0.45, 0.57)$) and BMI ($t=1.76 w/df=81, p = 0.08, 95\%CI (-0.18, 3.03)$).
 251
 252 Univariate and multivariate analysis were conducted to show the relationship of factors at the start
 253 of intervention with the decrease in blood pressure and blood glucose level. The factors to include
 254 in the univariate and multivariate analysis were selected based on being significant risk factors for
 255 hypertensive or diabetic. There were no factors related to decrease in blood pressure and glucose
 256 blood level at the univariate analysis, although at multivariate analysis, age above 50 years and
 257 being obese at the start of intervention were related to decrease in blood pressure level *Table 4*.

258
 259 **Table 4: Association between risk factors and decreased blood pressure or blood glucose**
 260 **among 76 people living with HIV/AIDS after three months of intervention in a Care and**
 261 **Treatment Center in Dar es Salaam, Tanzania in 2020**

Characteristics	Crude OR	P-value	95% CI	Adjusted OR	P-value	95% CI
Sex						
Male	1			1		
Female	1.50	0.21	0.80-2.81	1.22	0.55	0.63-2.37
Age group in years						
18-39	1			1		
40-49	1.57	0.64	0.24-10.49	1.78	0.14	0.83-3.82
50-75	0.96	0.97	0.16-5.93	2.27	0.04	1.04-4.96
Residence,						
Other districts	1					

Temeke	0.54	1.75	0.84—18.0			
Marital status						
Underweight	1			1		
Normal	0.66	0.49	0.20-2.15	1		
Overweight	0.75	0.65	0.22-2.60	1.49	0.24	0.77-2.88
Obese	Omitted			2.56	0.01	1.30-5.05
Marital status						
Single	1					
Married/Cohabiting	0.98	0.96	0.46-2.12			
Divorced/Separated	1.44	0.35	0.66-3.14			
Widow/Widower	1.82	0.16	0.79-4.18			
Physical activities (WHO)						
Met Standard	1					
Did not meet the standard	0.29	0.13	0.06-1.42	1.23	0.53	0.65-2.32

262

263

264 **Adherence to diabetic and hypertensive medication:**

265 Three focused group discussions were conducted, 10 participants and 10 healthcare workers were
 266 interviewed to explore the understanding of the participants on various risk factors for
 267 hypertension and diabetes. Also, barriers to care and adherence were discussed. Pre-defined
 268 questions were created to guide the discussion. After enough information was collected the
 269 discussion was stopped. Responses were documented during the focus group by one of the project
 270 implementers in a paper for reference during report writing.

271

272 Almost all participants had good knowledge of hypertension and diabetes. From the discussion,
 273 the most reported challenges to adherence to medication were lack of money to buy medication,

274 unaffordable consultation fees, and medication side effects. Most of the participants didn't know
275 the type of medication regimen they are taking, while others never took medication after diagnosis
276 or even after hypertensive and diabetic disease medication have been prescribed. Few reported
277 taking medication when they develop some hypertensive or diabetic symptoms as most other f
278 time were asymptomatic. The main reason was the high cost of medication or feeling well even
279 after diagnosis. Additionally, other participants were diagnosed and kept on treatment for either
280 HTN or DM other than the current clinic but never reported that they were on treatment. Health
281 care workers reported the absence of a specialized NCDs clinic at the Care and Treatment Center
282 (CTC). They also have no current knowledge of the management of hypertension and diabetes to
283 PLHIV. They have reported having no access to routine physical and biochemical checkup at the
284 clinic hence rendering them to miss patients suffering from NCDs.

285

286

287 **DISCUSSION**

288 In this project, we found that integration of hypertension (HTN) and diabetes (DM) prevention
289 efforts among PLHIV attending care is suboptimal in a care and treatment clinic. Most PLHIV
290 reported to never measured their blood pressure and some had a silent disease that was not
291 diagnosed at the clinic due to the absence of routine screening of NCDs among PLHIV. The risk
292 of having hypertension among PLHIV was high in obese patients and diabetic patients. The project
293 also revealed that PLHIV with other NCDs co-morbidities do not adhere to NCDs medication due
294 to high medication costs and having a silent disease. Health care workers providing HIV care do
295 not have up-to-date knowledge on hypertension and diabetic care rendering it difficult providing
296 of NCDs care among PLHIV. Close follow-up on hypertension and diabetes among PLHIV was
297 found to be productive due to a significant decrease in mean systolic and diastolic blood pressures
298 at the end of the follow-up period.

299

300 In our study, many HIV-positive were not screened for hypertension and diabetes in the facility
301 revealing missed opportunities to diagnose other co-morbidities among PLHIV. Due to the absence
302 of routine screening and care of hypertension and diabetes at the clinic, patients although known
303 to have hypertension did not report on their conditions to health facilities. This is similar to the
304 results found in Malawi and other parts of Africa where there was low integration of NCDs care
305 in PLHIV (15,19,24). This result contradicts results obtained in another study in Tanzania which
306 reveals the integration of care to be practiced in some health facilities with high acceptability of
307 the model (25). The main reason for these findings is probably due to HIV care settings that do not
308 mandate the clinician to provide NCDs care among PLHIV. As this has not been the practice,
309 health care providers in CTC did not have up-to-date information regarding the provision of NCDs

310 care among PLHIV similar to the findings from a study done in South Africa (26). Findings from
311 our study call for the country to ensure health care professionals providing HIV care to be well
312 trained on providing comprehensive care that also includes NCDs care apart from focusing on only
313 HIV services.

314
315 Hypertension is a major risk factor for heart diseases however this is not well known among
316 PLHIV (15,27–29). Our project found the prevalence of HTN to be 21.32%. This prevalence is
317 lower compared to the estimated prevalence of 26% in the general population in Tanzania (30).
318 Similar findings were obtained in a study conducted in Senegal (31). The prevalence of
319 hypertension observed in this study is higher compared to a study which was conducted in rural
320 Tanzania which found the prevalence of hypertension to be 11.6% (9,32). However, it was lower
321 than that reported by studies conducted elsewhere in Mbeya and Ethiopia (32,33). The results in
322 this project could be explained due to the nature of the project which relied on convenience
323 sampling.

324
325 Obesity was found to be an important risk factor for the development of hypertension in the current
326 study. This finding were obtained in this study suggesting that obesity may lead to the development
327 of hypertension. Similar findings were found in other studies conducted in Tanzania and other
328 countries in Africa (31–33). These finding could be explained by the growing evidence that
329 increased visceral fat in the body is a pathological depot that leadeth to accumulation of more
330 visceral fat in tissues (34,35). Visceral fat have been linked to increased inflammatory reactions in
331 endothelial cells of the blood vessels due to its sensitivity to lipolysis leading to endothelial
332 dysfunction and arterial hypertension (34,35). More evidence from different studies shows that

333 increased prevalence of overweight and obesity has caused increased burden of hypertension
334 (36,37). These findings add to the evidence that as BMI is easily measured and widely accessible
335 it remains to be a simple and effective tool for screening hypertension in public practice.

336
337 In our study, diabetes was also associated with hypertension. Similar findings were found in a
338 study that was conducted in Northeast Ethiopia (33). These findings further add to the evidence
339 that diabetes is a risk factor for hypertension and adds up to the burden of HIV and the need for
340 screening diabetes for all hypertensive HIV-positive patients (38,39).

341
342 Furthermore, our project found a significant change in blood pressure after three months of
343 intervention both for systolic and diastolic blood pressure showing the effectiveness of the
344 intervention. These findings were similar to findings in a study conducted in Bangladesh although
345 only physical and behavioral measurements were considered and not biochemical and blood
346 pressure levels (16). Our project showed no significant change in BMI value, while a study in
347 Bangladesh showed a significant change in the level of physical activity which might result in a
348 change in BMI value (16).

349
350 This project was conducted in an HIV setting where normal clinic visits took place so did not result
351 in disruption of care to PLHIV. Although risk factors were identified and added to the evidence,
352 information cannot be generalized elsewhere in Tanzania but can be used as a model to better
353 research studies and program implementation. Participants were not randomly selected so some
354 findings are prone to bias, this was because the study focused on control program, or prevention
355 program and provide concise documentation to that effect. The other important limitation is that

356 the project was implemented during the COVID-19 pandemic which affected every part of the
357 world. In our study, it has affected the scheduled patient follow-up clinic and measurements as
358 PLHIV were among the group prone to infection hence they were given long clinic visits to avoid
359 congestion at the clinic. Few HCWs were also scheduled in shifts to attend a clinic due to lack of
360 protective gear, hence further hindering consultative services to hypertensive patients. To
361 overcome this we used phone calls to follow-up patients and extension of time for clinic followup
362 to guarantee that all 76 clients in the cohort managed to have second test for both blood pressure
363 and blood glucose.

364

365 **CONCLUSION AND RECOMMENDATION**

366 Our project found that most HIV-positive patients are not screened for hypertension or other
367 NCDs. On top of that, we found that health education and close follow-up using surveillance
368 database is of importance for monitoring of patients. We found also that, adherence to antidiabetic
369 and antihypertensive medication is inadequate due to the high cost of medication and lack of
370 follow-up and monitoring. Also, the project found that being obese and diabetic are the risk factors
371 for hypertension. Working in the government or private organization and stage four HIV disease
372 were associated with lower risk for hypertension. Overall, our project has shown that integration
373 of NCDs care in HIV clinics is possible and health education-based intervention at health facilities
374 can result in positive change if practiced effectively. This method can be recommended as a
375 promising strategy in reducing the NCD burden among PLHIV.

376

377 We recommend the integration of NCDs and HIV services in Tanzania. Also we recommend the
378 need to strengthen health education and screening of NCDs as the prevalence continues to grow

379 among PLHIV and significant changes are observed with the creation of awareness. The cost of
380 antihypertensive and antidiabetic medication needs to be affordable, especially to PLHIV. We
381 recommend also more robust methodological studies on the integration of NCDs care among
382 PLHIV to make evidence-based information using a big sample size with all inclusive and
383 exclusive criteria into consideration.

384 **ACKNOWLEDGEMENT**

385 The authors wish to thank the The Centers for Disease Control and Prevention (CDC) for financial
386 support.

387

388 **AUTHOR CONTRIBUTION:**

389 Conceptualization: AM, GM, EM.

390 Data curation: AM, GM.

391 Formal analysis: AM, GM, EM.

392 Funding acquisition: AM.

393 Investigation: AM.

394 Methodology:AM, GM, EM.

395 Project administration: AM.

396 Software: AM.

397 Supervision: MM, RK, AT, LB, MS.

398 Validation:MS . Visualization: AM.

399 Writing – original draft: AM. Writing – review& editing: AD,MM,AT

400

401

402

403

404

405

406

407 **REFERENCES**

408

- 409 1. Chigom E. DEVELOPMENT OF AN IMPLEMENTATION ROADMAP 2023–2030
410 FOR THE GLOBAL ACTION PLAN FOR THE PREVENTION AND CONTROL OF
411 NCDS 2013–203. World Health. 2020.
- 412 2. United Republic of Tanzania. Strategic and action plan for the prevention and control of
413 Non Communicable Diseases in Tanzania 2016-2020. 2020.
- 414 3. Redaktion D. Non-communicable diseases: Editorial. Vol. 24, Public Health Forum. 2016.
415 69 p.
- 416 4. World Health Organization (WHO). GLOBAL ACTION PLAN FOR THE
417 PREVENTION AND CONTROL OF NONCOMMUNICABLE DISEASES. 2013.
- 418 5. Of R, Death P, To DUE. UNITED REPUBLIC OF TANZANIA. 2018;2018.
- 419 6. Andrade J. United Republic of Tanzania. World Police & Paramilitary Forces. 2016;199–
420 199.
- 421 7. TACAIDS. The United Republic of Tanzania Tanzania Commission for Aids National
422 HIV and AIDS Response Report for 2017. 2017;(June). Available from:
423 [http://library.tacaids.go.tz/bitstream/handle/123456789/134/National HIV and AIDS](http://library.tacaids.go.tz/bitstream/handle/123456789/134/National%20HIV%20and%20AIDS%20Response%20Report%20for%202017%20-%20Tanzania%20Mainland.pdf?sequence=1&isAllowed=y)
424 [Response Report for 2017 - Tanzania Mainland.pdf?sequence=1&isAllowed=y](http://library.tacaids.go.tz/bitstream/handle/123456789/134/National HIV and AIDS Response Report for 2017 - Tanzania Mainland.pdf?sequence=1&isAllowed=y)
- 425 8. Mathebula RL, Maimela E, Ntuli NS. The prevalence of selected non-communicable
426 disease risk factors among HIV patients on anti-retroviral therapy in Bushbuckridge sub-
427 district, Mpumalanga province. BMC Public Health. 2020;20(1):1–10.
- 428 9. Furrer H, Hatz C, Tanner M, Battegay M, Letang E, Study K. Incidence and risk factors
429 for hypertension among HIV patients in rural Tanzania – A prospective cohort study.

- 430 2017;630(Ci):1–14.
- 431 10. Divala OH, Amberbir A, Ismail Z, Beyene T, Garone D, Pfaff C, et al. The burden of
432 hypertension, diabetes mellitus, and cardiovascular risk factors among adult Malawians in
433 HIV care: consequences for integrated services. *BMC Public Health*. 2016;16(1):1–11.
- 434 11. IAPAC. IAPAC Protocols for the Integrated Management of HIV and Noncommunicable
435 Diseases [Internet]. International association of providers of AIDS care. 2018. Available
436 from: [https://www.iapac.org/files/2018/07/IAPAC-Protocols-for-the-Integrated-](https://www.iapac.org/files/2018/07/IAPAC-Protocols-for-the-Integrated-Management-of-HIV-and-Noncommunicable-Diseases_3.pdf)
437 [Management-of-HIV-and-Noncommunicable-Diseases_3.pdf](https://www.iapac.org/files/2018/07/IAPAC-Protocols-for-the-Integrated-Management-of-HIV-and-Noncommunicable-Diseases_3.pdf)
- 438 12. Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of
439 Diabetes Mellitus in Persons with and without HIV: A Danish Nationwide Population-
440 Based Cohort Study. *PLoS One*. 2012;7(9):18–22.
- 441 13. Duncan AD, Goff LM, Peters BS. Type 2 diabetes prevalence and its risk factors in HIV:
442 A cross-sectional study. *PLoS One*. 2018;13(3):1–11.
- 443 14. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas : Global estimates of the
444 prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract* [Internet].
445 2011;94(3):311–21. Available from: <http://dx.doi.org/10.1016/j.diabres.2011.10.029>
- 446 15. Pfaff C, Scott V, Hoffman R, Mwangomba B. You can treat my HIV - But can you treat my
447 blood pressure? Availability of integrated HIV and noncommunicable disease care in
448 northern Malawi. *African J Prim Heal Care Fam Med*. 2017;9(1):1–8.
- 449 16. Mondal R, Sarker RC, Acharya NP, Banik PC. Effectiveness of health education-based
450 conventional intervention method to reduce noncommunicable diseases risk factors among
451 rural population. *Cardiovasc Diagn Ther*. 2019;9(1):30–4.
- 452 17. IAPAC Protocols for the Integrated Management of HIV and Noncommunicable

- 453 Diseases. 2018;(July).
- 454 18. WHO. Integrated care models: an overview [Internet]. Health Services Delivery
455 Programme. 2016. Available from: [http://www.euro.who.int/en/health-topics/Health-](http://www.euro.who.int/en/health-topics/Health-systems/health-services-delivery/publications/2016/integrated-care-models-an-overview-2016)
456 [systems/health-services-delivery/publications/2016/integrated-care-models-an-overview-](http://www.euro.who.int/en/health-topics/Health-systems/health-services-delivery/publications/2016/integrated-care-models-an-overview-2016)
457 2016
- 458 19. Nigatu T. Integration of HIV and noncommunicable diseases in health care delivery in
459 low- and middle-income countries. *Prev Chronic Dis*. 2012;9(5):9–11.
- 460 20. World Health Organization (WHO). WHO Integrating noncommunicable disease services
461 into primary health care, Botswana. p. 73–168.
- 462 21. Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV DATA -2019. 2019.
- 463 22. MoHCDGEC (Tanzania Ministry of Health, Community Development, Gender E and,
464 Children). Strategic and Action Plan for the Prevention and Control of Non
465 Communicable Diseases in Tanzania 2016 – 2020. Dar es Salaam; 2016.
- 466 23. Patel P, Rose CE, Collins PY, Nuche-berenguer B, Sahasrabudhe V V, Peprah E, et al.
467 Noncommunicable diseases among HIV-infected persons in low-income and middle-
468 income countries: a systematic review and meta-analysis. 2019;32(Suppl 1):1–28.
- 469 24. Torpey K, Mastro TD. Discussion paper on how to promote the inclusion of the
470 prevention and control of noncommunicable diseases within other programmatic areas.
471 2016.
- 472 25. Shayo EH, Seeley J, Bukenya D, Karoli P, Jaffar S. The Acceptability of Integrated
473 Healthcare Services for HIV and Non-Communicable Diseases: Experiences from Patients
474 and Healthcare Workers in Tanzania. *Res Sq* [Internet]. 2021;1–22. Available from:
475 <https://www.researchsquare.com/article/rs-796756/latest.pdf>

- 476 26. Godongwana M, Wet-billings N De, Milovanovic M. The comorbidity of HIV ,
477 hypertension and diabetes : a qualitative study exploring the challenges faced by
478 healthcare providers and patients in selected urban and rural health facilities where the
479 ICDM model is implemented in South Africa. 2021;3:1–15.
- 480 27. Global status report on noncommunicable diseases. 2010;
- 481 28. Mse YX, Chen X, Mse KW. Global prevalence of hypertension among people living with
482 HIV : A Global prevalence of hypertension among people living with HIV : a systematic
483 review and. J Am Soc Hypertens [Internet]. 2017;(June). Available from:
484 <http://dx.doi.org/10.1016/j.jash.2017.06.004>
- 485 29. Mayige M, Kagaruki G, Ramaiya K, Swai A. Non communicable diseases in Tanzania : a
486 call for urgent action. 2012;14(2):1–12.
- 487 30. WHO. Mongolian STEPS survey on the prevalence of noncommunicable disease and
488 injury risk factors 2009 [Internet]. WHO Library. 2010. Available from: [internal-
pdf://202.115.27.218/Mongolia_2013_STEPS_Report.pdf](https://www.who.int/ncds/surveillance/steps/Mongolia_2013_STEPS_Report.pdf)
489 [https://www.who.int/ncds/
490 surveillance/steps/Mongolia_2013_STEPS_Report.pdf](https://www.who.int/ncds/surveillance/steps/Mongolia_2013_STEPS_Report.pdf)
- 491 31. Africa W, Id NAB, Seydi M, Doye IN, Toure M, Sy P, et al. Increasing prevalence of
492 hypertension among HIV-positive and negative adults in Senegal ., 2018;1–14.
- 493 32. Kagaruki GB, Mayige MT, Ngadaya ES, Kimaro GD, Kalinga AK, Kilale AM, et al.
494 Magnitude and risk factors of non-communicable diseases among people living with HIV
495 in Tanzania: A cross sectional study from Mbeya and Dar es Salaam regions. BMC Public
496 Health. 2014;14(1):1–9.
- 497 33. Fiseha T, Belete AG, Dereje H, Dires A. Hypertension in HIV-Infected Patients Receiving
498 Antiretroviral Therapy in Northeast Ethiopia. 2019;2019.

- 499 34. Khan M, Joseph F. Adipose Tissue and Adipokines: The Association with and Application
500 of Adipokines in Obesity. *Scientifica (Cairo)*. 2014;2014:1–7.
- 501 35. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of
502 adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and
503 subcutaneous abdominal adipose tissues of obese humans. *Endocrinology*.
504 2004;145(5):2273–82.
- 505 36. Landi F, Calvani R, Picca A, Tosato M, Martone AM, Ortolani E, et al. Body mass index
506 is strongly associated with hypertension: Results from the longevity check-up 7+ study.
507 *Nutrients*. 2018;10(12):1–12.
- 508 37. Chen Y, Liang X, Zheng S, Wang Y, Lu W. Association of body fat mass and fat
509 distribution with the incidence of hypertension in a population-based Chinese cohort: A
510 22-year follow-up. *J Am Heart Assoc*. 2018;7(6):1–9.
- 511 38. Spollett GR. Hyperglycemia in HIV / AIDS. :163–6.
- 512 39. Mayige M, Kagaruki G, Ramaiya K, Swai A. Non communicable diseases in Tanzania: A
513 call for urgent action. *Tanzan J Health Res*. 2011;13(5 SUPPL.ISS):1–11.
- 514